Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nursing Homes | 19 | 2025 | 672 | 1.640 |
Why?
|
| Analgesics, Opioid | 11 | 2025 | 536 | 1.070 |
Why?
|
| Dietary Supplements | 3 | 2021 | 235 | 1.020 |
Why?
|
| Pharmacy | 2 | 2022 | 19 | 1.010 |
Why?
|
| Education, Pharmacy | 5 | 2020 | 18 | 0.920 |
Why?
|
| Complementary Therapies | 2 | 2018 | 62 | 0.800 |
Why?
|
| Students, Pharmacy | 3 | 2020 | 13 | 0.780 |
Why?
|
| Homes for the Aged | 5 | 2020 | 161 | 0.680 |
Why?
|
| Vaccines | 1 | 2022 | 98 | 0.680 |
Why?
|
| Pharmacists | 7 | 2020 | 127 | 0.670 |
Why?
|
| Drug Utilization | 6 | 2021 | 209 | 0.550 |
Why?
|
| Hospice Care | 1 | 2018 | 68 | 0.540 |
Why?
|
| Evidence-Based Medicine | 3 | 2010 | 462 | 0.540 |
Why?
|
| Palliative Care | 2 | 2020 | 235 | 0.520 |
Why?
|
| Atrial Fibrillation | 5 | 2025 | 838 | 0.490 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2021 | 215 | 0.450 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2020 | 709 | 0.450 |
Why?
|
| Warfarin | 4 | 2025 | 112 | 0.450 |
Why?
|
| Alzheimer Disease | 1 | 2021 | 722 | 0.440 |
Why?
|
| Pain | 5 | 2023 | 407 | 0.440 |
Why?
|
| Medicare | 10 | 2023 | 613 | 0.410 |
Why?
|
| Aged | 29 | 2025 | 14481 | 0.410 |
Why?
|
| Humans | 49 | 2025 | 63587 | 0.400 |
Why?
|
| Aged, 80 and over | 20 | 2025 | 5483 | 0.390 |
Why?
|
| Anticoagulants | 5 | 2025 | 495 | 0.380 |
Why?
|
| United States | 22 | 2025 | 7852 | 0.380 |
Why?
|
| Stroke | 5 | 2025 | 1189 | 0.370 |
Why?
|
| Skilled Nursing Facilities | 5 | 2021 | 81 | 0.370 |
Why?
|
| Aspirin | 2 | 2011 | 172 | 0.370 |
Why?
|
| Activities of Daily Living | 4 | 2021 | 292 | 0.360 |
Why?
|
| Electronic Prescribing | 1 | 2011 | 11 | 0.350 |
Why?
|
| Epilepsy | 2 | 2023 | 111 | 0.330 |
Why?
|
| Pain Management | 4 | 2024 | 163 | 0.330 |
Why?
|
| Fibrinolytic Agents | 1 | 2011 | 170 | 0.330 |
Why?
|
| Cardiovascular Diseases | 2 | 2011 | 844 | 0.320 |
Why?
|
| Professional Role | 3 | 2016 | 44 | 0.320 |
Why?
|
| Vitamins | 1 | 2010 | 80 | 0.310 |
Why?
|
| Integrative Medicine | 2 | 2021 | 32 | 0.310 |
Why?
|
| Drug Therapy | 2 | 2010 | 56 | 0.300 |
Why?
|
| Patient Selection | 1 | 2011 | 491 | 0.300 |
Why?
|
| Computers, Handheld | 2 | 2005 | 38 | 0.290 |
Why?
|
| Female | 27 | 2025 | 32979 | 0.290 |
Why?
|
| Physicians | 2 | 2011 | 475 | 0.280 |
Why?
|
| Primary Health Care | 2 | 2011 | 697 | 0.280 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2017 | 143 | 0.270 |
Why?
|
| Malabsorption Syndromes | 1 | 2007 | 3 | 0.270 |
Why?
|
| Chronic Pain | 3 | 2024 | 154 | 0.270 |
Why?
|
| Attitude of Health Personnel | 2 | 2011 | 606 | 0.270 |
Why?
|
| Hospitalization | 5 | 2025 | 1361 | 0.260 |
Why?
|
| Professional-Patient Relations | 1 | 2008 | 129 | 0.260 |
Why?
|
| Gastric Bypass | 1 | 2007 | 76 | 0.250 |
Why?
|
| Delirium | 2 | 2025 | 54 | 0.250 |
Why?
|
| Algorithms | 1 | 2011 | 1005 | 0.240 |
Why?
|
| Anticonvulsants | 3 | 2023 | 104 | 0.240 |
Why?
|
| Administration, Oral | 5 | 2025 | 370 | 0.230 |
Why?
|
| Drug Prescriptions | 3 | 2020 | 168 | 0.230 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2025 | 79 | 0.220 |
Why?
|
| Male | 23 | 2025 | 29967 | 0.220 |
Why?
|
| Community Health Services | 1 | 2005 | 128 | 0.220 |
Why?
|
| Communication | 2 | 2012 | 580 | 0.210 |
Why?
|
| Retrospective Studies | 11 | 2025 | 6646 | 0.210 |
Why?
|
| Clonazepam | 1 | 2023 | 3 | 0.210 |
Why?
|
| Cross-Sectional Studies | 9 | 2021 | 2588 | 0.210 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2023 | 10 | 0.200 |
Why?
|
| Rivaroxaban | 2 | 2023 | 19 | 0.200 |
Why?
|
| Dabigatran | 2 | 2023 | 20 | 0.200 |
Why?
|
| Analgesics | 2 | 2021 | 102 | 0.200 |
Why?
|
| Embolism | 1 | 2023 | 42 | 0.190 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 36 | 0.190 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 150 | 0.190 |
Why?
|
| Fractures, Bone | 2 | 2025 | 143 | 0.180 |
Why?
|
| Immunization | 1 | 2022 | 133 | 0.180 |
Why?
|
| Heart Failure | 3 | 2017 | 915 | 0.180 |
Why?
|
| Neuralgia | 1 | 2021 | 21 | 0.180 |
Why?
|
| Liver Diseases | 1 | 2023 | 155 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 791 | 0.170 |
Why?
|
| Oxycodone | 2 | 2018 | 30 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 89 | 0.160 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2017 | 151 | 0.160 |
Why?
|
| Vaccination | 1 | 2022 | 364 | 0.160 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2019 | 7 | 0.150 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2021 | 123 | 0.150 |
Why?
|
| Cancer Pain | 1 | 2019 | 16 | 0.150 |
Why?
|
| Patient-Centered Care | 3 | 2016 | 254 | 0.150 |
Why?
|
| Program Development | 2 | 2018 | 207 | 0.150 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2017 | 65 | 0.150 |
Why?
|
| Geographic Mapping | 1 | 2018 | 8 | 0.150 |
Why?
|
| Medicare Part D | 4 | 2020 | 36 | 0.150 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 162 | 0.150 |
Why?
|
| Self Care | 1 | 2020 | 214 | 0.150 |
Why?
|
| Risk Assessment | 4 | 2011 | 2045 | 0.140 |
Why?
|
| Cohort Studies | 5 | 2023 | 2575 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2020 | 427 | 0.130 |
Why?
|
| Morphine | 1 | 2016 | 59 | 0.120 |
Why?
|
| Fentanyl | 1 | 2016 | 76 | 0.120 |
Why?
|
| Stroke Volume | 1 | 2017 | 329 | 0.120 |
Why?
|
| Delayed-Action Preparations | 3 | 2025 | 115 | 0.120 |
Why?
|
| Prevalence | 4 | 2021 | 1387 | 0.120 |
Why?
|
| Biological Products | 1 | 2016 | 96 | 0.110 |
Why?
|
| Middle Aged | 9 | 2025 | 17682 | 0.110 |
Why?
|
| Brain Ischemia | 1 | 2019 | 421 | 0.110 |
Why?
|
| Hemorrhage | 3 | 2023 | 267 | 0.110 |
Why?
|
| Internet | 3 | 2012 | 469 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2018 | 727 | 0.100 |
Why?
|
| Biomedical Research | 2 | 2007 | 269 | 0.100 |
Why?
|
| Brain | 1 | 2021 | 1556 | 0.100 |
Why?
|
| Videodisc Recording | 1 | 2012 | 8 | 0.100 |
Why?
|
| Community Pharmacy Services | 1 | 2012 | 13 | 0.100 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2012 | 20 | 0.100 |
Why?
|
| Interprofessional Relations | 2 | 2018 | 136 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 723 | 0.090 |
Why?
|
| Proportional Hazards Models | 4 | 2018 | 731 | 0.090 |
Why?
|
| Software Design | 1 | 2011 | 28 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2012 | 121 | 0.090 |
Why?
|
| Comorbidity | 3 | 2020 | 1117 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 1556 | 0.090 |
Why?
|
| Health Education | 1 | 2012 | 190 | 0.090 |
Why?
|
| Continuity of Patient Care | 1 | 2012 | 174 | 0.090 |
Why?
|
| Accidental Falls | 2 | 2025 | 127 | 0.090 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2011 | 73 | 0.080 |
Why?
|
| Drug Resistance | 1 | 2011 | 153 | 0.080 |
Why?
|
| Patient Safety | 1 | 2012 | 243 | 0.080 |
Why?
|
| Patient Education as Topic | 2 | 2016 | 477 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2025 | 864 | 0.080 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 24 | 0.070 |
Why?
|
| Sex Factors | 1 | 2011 | 974 | 0.070 |
Why?
|
| Ethics, Pharmacy | 1 | 2008 | 3 | 0.070 |
Why?
|
| Keratinocytes | 1 | 2008 | 63 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2025 | 5669 | 0.070 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2008 | 66 | 0.070 |
Why?
|
| Drug Industry | 1 | 2008 | 39 | 0.070 |
Why?
|
| Tramadol | 2 | 2018 | 16 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 763 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 2467 | 0.070 |
Why?
|
| Models, Statistical | 2 | 2005 | 308 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 541 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 259 | 0.060 |
Why?
|
| Urinary Tract Infections | 1 | 2007 | 92 | 0.060 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 144 | 0.060 |
Why?
|
| Information Storage and Retrieval | 1 | 2005 | 60 | 0.060 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2005 | 25 | 0.060 |
Why?
|
| Lorazepam | 1 | 2023 | 8 | 0.050 |
Why?
|
| Diazepam | 1 | 2023 | 10 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 411 | 0.050 |
Why?
|
| Valproic Acid | 1 | 2023 | 24 | 0.050 |
Why?
|
| Time Factors | 2 | 2019 | 3732 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2023 | 103 | 0.050 |
Why?
|
| South Dakota | 1 | 2002 | 4 | 0.050 |
Why?
|
| Mississippi | 1 | 2002 | 16 | 0.050 |
Why?
|
| Maine | 1 | 2002 | 18 | 0.050 |
Why?
|
| Risk Factors | 3 | 2020 | 5316 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2005 | 851 | 0.050 |
Why?
|
| New York | 1 | 2002 | 145 | 0.050 |
Why?
|
| Medical Informatics | 2 | 2012 | 73 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2023 | 172 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2023 | 205 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 456 | 0.040 |
Why?
|
| Myocardial Ischemia | 1 | 2002 | 117 | 0.040 |
Why?
|
| Prognosis | 2 | 2005 | 1746 | 0.040 |
Why?
|
| Societies, Pharmaceutical | 2 | 2012 | 2 | 0.040 |
Why?
|
| Curriculum | 2 | 2018 | 602 | 0.040 |
Why?
|
| Narcotics | 1 | 2021 | 58 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 101 | 0.040 |
Why?
|
| Incidence | 2 | 2018 | 1380 | 0.040 |
Why?
|
| Neuromuscular Agents | 1 | 2020 | 16 | 0.040 |
Why?
|
| Prescription Drug Misuse | 1 | 2020 | 21 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 158 | 0.040 |
Why?
|
| Analgesia | 1 | 2020 | 31 | 0.040 |
Why?
|
| Pregnancy | 1 | 2007 | 2335 | 0.040 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2020 | 76 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2020 | 61 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2019 | 42 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 485 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 141 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2020 | 226 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 189 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 68 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2018 | 73 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 286 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2018 | 164 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 1 | 2018 | 96 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 163 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 378 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2018 | 345 | 0.030 |
Why?
|
| Drug and Narcotic Control | 1 | 2016 | 28 | 0.030 |
Why?
|
| Oxymorphone | 1 | 2016 | 5 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 753 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2016 | 32 | 0.030 |
Why?
|
| Rhode Island | 1 | 2016 | 100 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2017 | 165 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2018 | 286 | 0.030 |
Why?
|
| Long-Term Care | 1 | 2016 | 177 | 0.030 |
Why?
|
| Adult | 2 | 2012 | 16904 | 0.030 |
Why?
|
| Research Design | 2 | 2008 | 575 | 0.030 |
Why?
|
| Buprenorphine | 1 | 2016 | 193 | 0.020 |
Why?
|
| Pharmacology, Clinical | 1 | 2012 | 2 | 0.020 |
Why?
|
| Medication Reconciliation | 1 | 2012 | 13 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2012 | 121 | 0.020 |
Why?
|
| Cultural Diversity | 1 | 2012 | 54 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 915 | 0.020 |
Why?
|
| Depression | 1 | 2018 | 908 | 0.020 |
Why?
|
| Logistic Models | 2 | 2005 | 1275 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2012 | 215 | 0.020 |
Why?
|
| Geriatrics | 1 | 2010 | 43 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2012 | 367 | 0.020 |
Why?
|
| Teaching | 1 | 2010 | 161 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2010 | 219 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2012 | 445 | 0.020 |
Why?
|
| Confidentiality | 1 | 2008 | 56 | 0.020 |
Why?
|
| Conflict of Interest | 1 | 2008 | 37 | 0.020 |
Why?
|
| Disclosure | 1 | 2008 | 56 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2007 | 59 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2007 | 93 | 0.020 |
Why?
|
| Organizational Innovation | 1 | 2007 | 82 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2007 | 105 | 0.020 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 174 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2007 | 487 | 0.010 |
Why?
|
| Bias | 1 | 2004 | 112 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2005 | 498 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 127 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2002 | 585 | 0.010 |
Why?
|
| Hypertension | 1 | 2005 | 590 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2704 | 0.010 |
Why?
|